NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on Heron Therapeutics, Inc. (NASDAQ: HRTX)
Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $28 on shares of Heron Therapeutics, Inc.’s (NASDAQ: HRTX) stock. The company currently has two drugs in development in the chemotherapy-induced nausea and vomiting (CINV) space. Its lead product, Sustol, is in the commercial stage, while Cinvanti is up for approval in November 2017. Heron expects to launch Cinvanti in the first quarter of 2018. The analyst believes that the company’s potential to have two CINV drugs targeting two sides of a $900 million market is underappreciated and predicts that Heron will reach break-even in…







